Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
reactogenicity
Description:
The capacity of a vaccine or other intervention to cause expected adverse reactions, especially immune-related symptoms.
Related topics:
Bacterial Infections and Vaccines (16%),
SARS-CoV-2 and COVID-19 Research (15%),
Influenza Virus Research Studies (14%)
Wikidata ID:
wiki/Q7300322
OpenAlex ID:
keywords/reactogenicity
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
2020
·
Lindsey R. Baden
, Hana M. El Sahly
, et al.
·
New England Journal of Medicine
·
11,160
PDF
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
2021
·
Jerald Sadoff
, Glenda Gray
, et al.
·
New England Journal of Medicine
·
2,598
PDF
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
2020
·
Pedro M Folegatti
, Katie J Ewer
, et al.
·
The Lancet
·
2,584
PDF
The role of lipid components in lipid nanoparticles for vaccines and gene therapy
2022
·
Camilla Hald Albertsen
, Jayesh A. Kulkarni
, et al.
·
Advanced Drug Delivery Reviews
·
1,345
PDF
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
2021
·
Jerald Sadoff
, Mathieu Le Gars
, et al.
·
New England Journal of Medicine
·
1,292
PDF
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
2020
·
Cheryl Keech
, Gary Albert
, et al.
·
New England Journal of Medicine
·
1,208
PDF
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
2021
·
Paul T. Heath
, Eva P. Galiza
, et al.
·
New England Journal of Medicine
·
1,172
PDF
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
2021
·
Robert W. Frenck
, Nicola P. Klein
, et al.
·
New England Journal of Medicine
·
970
PDF
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults
2023
·
Alberto Papi
, Michael G. Ison
, et al.
·
New England Journal of Medicine
·
895
PDF
Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study
2021
·
Kathryn J. Gray
, Evan A. Bordt
, et al.
·
American Journal of Obstetrics and Gynecology
·
781
PDF
Peptide Vaccine: Progress and Challenges
2014
·
Weidang Li
, Medha Joshi
, et al.
·
Vaccines
·
725
PDF
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
2021
·
Alasdair P S Munro
, Leila Janani
, et al.
·
The Lancet
·
713
PDF
Homologous and Heterologous Covid-19 Booster Vaccinations
2022
·
Robert L. Atmar
, Kirsten E. Lyke
, et al.
·
New England Journal of Medicine
·
677
PDF
A Bivalent Omicron-Containing Booster Vaccine against Covid-19
2022
·
Spyros Chalkias
, Charles Harper
, et al.
·
New England Journal of Medicine
·
651
PDF
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
2021
·
Emmanuel B. Walter
, Kawsar R. Talaat
, et al.
·
New England Journal of Medicine
·
649
PDF
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
2021
·
Vivek Shinde
, Sutika Bhikha
, et al.
·
New England Journal of Medicine
·
646
Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba.
1991
·
G V Sierra
, H C Campa
, et al.
·
PubMed
·
602
Safety and Efficacy of a Recombinant Hepatitis E Vaccine
2007
·
Mrigendra Prasad Shrestha
, Robert McNair Scott
, et al.
·
New England Journal of Medicine
·
595
The dawn of mRNA vaccines: The COVID-19 case
2021
·
Rein Verbeke
, Ine Lentacker
, et al.
·
Journal of Controlled Release
·
563
PDF
Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women
2006
·
Stan L. Block
, Terry Nolan
, et al.
·
PEDIATRICS
·
525
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
2021
·
Xinxue Liu
, Robert H Shaw
, et al.
·
The Lancet
·
508
PDF
mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials
2019
·
Robert A. Feldman
, Rainard Fuhr
, et al.
·
Vaccine
·
483
PDF
The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial
2017
·
Nadine G Rouphael
, Michele Paine
, et al.
·
The Lancet
·
473
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study
2022
·
Sue Ann Costa Clemens
, Lily Weckx
, et al.
·
The Lancet
·
456
PDF
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe
2015
·
Selidji T. Agnandji
, Angela Huttner
, et al.
·
New England Journal of Medicine
·
455
PDF
Show more works
View as search
Works count:
2,836
Citation count:
93,640
Year
Topic
Type